Citation tools
"Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial." Journal of Nuclear Medicine
62.supplement 1
(2021):
1311.
Web. 17 April. 2024.